Treatment of advanced colorectal carcinoma with AMSA.
AMSA in a dose of 120 mg/m2 iv every 4 weeks was evaluated in 26 patients with advanced measurable colorectal cancer, 13 of whom had had no prior chemotherapy. The schedule was tolerated well except by those patients who had prior irradiation or chemotherapy, in whom a dose reduction to 90 mg/m2 was required. No significant antitumor response was observed.
D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000009:adverse effects / Q000627:therapeutic use*; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D013921:Thrombocytopenia / Q000139:chemically induced
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine